AIIMS Jodhpur · AIIMS/JDH/SPH/2026/268
A Phase III, Multicentre, Randomized, double-Blind, Placebo Controlled study to Evaluate the Efficacy, Immunogenicity and Safety of Single dose of Dengue Tetravalent Vaccine, Live Attenuated (Recombinant, Lyophillized) – "DengiAll" of Panacea Biotec Limited in Healthy Indian Adults" under NHRP (Vector borne component) 2026
Applications closed closed 17 Jul 2026
All India Institute of Medical Sciences, Jodhpur is recruiting A Phase III, Multicentre, Randomized, double-Blind, Placebo Controlled study to Evaluate the Efficacy, Immunogenicity and Safety of Single dose of Dengue Tetravalent Vaccine, Live Attenuated (Recombinant, Lyophillized) – "DengiAll" of Panacea Biotec Limited in Healthy Indian Adults" under NHRP (Vector borne component). Applications opened 06 July and close 17 July 2026. Advertisement AIIMS/JDH/SPH/2026/268.
This drive does not publish a state-by-state vacancy table, or we have not been able to read one from it yet — so this page does not show one.
| Applications open | 06 Jul 2026 |
|---|---|
| Last date | 17 Jul 2026 |
| Age | up to 28 years |
| Age reckoned as on | 17 Jul 2026 |
| Qualification | 10th + Diploma (MLT/DMLT) |
| Fee | not read yet |
| Advertisement | AIIMS/JDH/SPH/2026/268 |
| Pay | Rs. 18,000/- + HRA, as admissible |
| Selection | Walk-In-Interview → Written examination |
| Documents | Passport-size photograph; Documents regarding age; Qualifications; Relevant experience; No Objection Certificate |
Blanks are ours, not the document's. Every filled value was read from the notification linked below; anything marked not read yet is a gap in our reading, not a field the recruiter left empty.
1783318334_Advertisement for DengiAll Project-060726.pdf
— the official AIIMSJ notification (aiimsj-table).Not checked. No state-by-state table could be read from this document, so there was no arithmetic to reconcile. The dates and identifiers above come from the document itself.
Fetched 02 Sep 2026, 01:06 UTC.